Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with nab-paclitaxel and lobaplatin for advanced esophageal squamous cell carcinoma
ChiCTR2000033338Phase 2Not yet recruiting
- Sponsor
- First Medical Center of Chinese PLA General Hospital
- Start
- Jul 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab, paclitaxel and lobaplatin in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by First Medical Center of Chinese PLA General Hospital. Primary endpoint: Progression-free survival. Planned start Jul 2020; status: not yet recruiting.
02
Drugs
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on ChiCTR2000033338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000033338.